Cyclosporine dosing study for stem cell transplant patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing a more personalized way to give the drug cyclosporine to people who have had a stem cell transplant. The goal is to prevent graft-versus-host disease (a common complication) by tailoring the dose to each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 65 years old.
- You must have already had your first stem cell transplant and be stable.
- You must need cyclosporine alone or with other drugs to prevent graft-versus-host disease.
- You must not have missed or incorrect timing of any doses or blood samples.
- You must have enough information about your health history and drug levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a drug combo (cyclophosphamide, sirolimus, and ruxolitinib) works better than another combo (cyclophosphamide, sirolimus, and mycophenolate mofetil) to prevent graft versus host disease in people getting a stem cell transplant for certain blood cancers.
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
This trial studies giving cyclophosphamide after a stem cell transplant when there is no matched sibling donor, but a well-matched unrelated donor is available. It aims to improve outcomes for people with blood cancers undergoing this transplant.
This early-phase study tests giving cyclophosphamide after a specific type of stem cell transplant (haploidentical) in people age 65 and older. It aims to improve transplant safety and outcomes by adjusting medicine given after the graft is placed.
This trial tests a lower dose of the drug cyclophosphamide after a stem cell transplant from a half-matched donor. It aims to see if the lower dose works just as well to prevent graft-versus-host disease, with fewer side effects.
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
Hear when a new Bone Marrow Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.